[Pharmacokinetic and clinical studies on flomoxef in perinatal period].
Pharmacokinetic and clinical studies on flomoxef (FMOX) in the perinatal period were carried out. The results are summarized as follows. 1. The concentration of FMOX in umbilical cord serum was about 10 micrograms/ml in about 30 minutes after 1 g one shot intravenous injection. Amniotic fluid concentration was 7 micrograms/ml in 41 minutes after administration. By 1 hour intravenous drip infusion, FMOX concentration in umbilical cord serum was about 5 micrograms/ml in 2-3 hours after administration. Amniotic fluid concentration of about 20 micrograms/ml was found in 1 case. 2. FMOX 1-2 g x 2-3/day was given by intravenous drip infusion to 7 cases of perinatal infection for 4-26 days. Clinical efficacies were evaluated a good for all cases. Neither side effect nor abnormal laboratory test value was observed. Consequently, FMOX was considered to be highly effective and safe for its clinical use in perinatal period infections.
Ito
K
K
Department of Obstetrics and Gynecology, School of Medicine, Gifu University.
Mikamo
H
H
Tamaya
T
T
Yamada
Y
Y
Hayasaki
M
M
D000328:Adult; D000653:Amniotic Fluid / Q000378:metabolism; D002511:Cephalosporins / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002821:Chorioamnionitis / Q000188:drug therapy; D004341:Drug Evaluation; D004716:Endometritis / Q000188:drug therapy; D005260:Female; D005312:Fetal Blood / Q000378:metabolism; D006801:Humans; D007262:Infusions, Intravenous; D007275:Injections, Intravenous; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy*; D011645:Puerperal Infection / Q000188:drug therapy*
D002511:Cephalosporins; C045693:flomoxef